Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	53.3	44.47	81.38	206.33	83.97	87.78
Short-Term Investments	145.35	167.73	201.12	0	225.19	37.53
Cash & Cash Equivalents	198.65	212.2	282.49	206.33	309.15	125.32
Cash Growth	-19.64%	-24.88%	36.92%	-33.26%	146.69%	312.30%
Receivables	12.03	9.01	9.09	0	0	0
Other Current Assets	6.06	5.26	6.98	7.55	4.84	1.86
Total Current Assets	216.73	226.48	298.56	213.87	314	127.18
Property, Plant & Equipment	39.22	40.78	46.67	48.23	48.32	10.86
Goodwill and Intangibles	5.55	5.55	5.55	5.55	5.55	5.55
Other Long-Term Assets	1.08	1.08	1.06	1.66	3.62	3.41
Total Long-Term Assets	45.85	47.41	53.27	55.44	57.49	19.82
Total Assets	262.58	273.89	351.84	269.31	371.48	147
Accounts Payable	2.7	3.27	2.23	8.96	0.76	4.93
Deferred Revenue	61.67	47.79	41.06	13.76	0	0
Current Debt	6	5.95	5.87	6.34	4.81	3
Other Current Liabilities	14.39	14.31	4.74	14.28	24.45	13.93
Total Current Liabilities	84.76	71.32	53.89	43.34	30.03	21.86
Long-Term Debt	78.57	79.47	82.89	54.86	54.51	26.14
Other Long-Term Liabilities	14.66	19.39	27.47	14.9	24.98	26.34
Total Long-Term Liabilities	93.22	98.87	110.36	69.76	79.49	52.48
Total Liabilities	177.99	170.18	164.24	113.1	109.52	74.33
Total Debt	84.56	85.42	88.75	61.2	59.32	29.14
Debt Growth	-3.79%	-3.75%	45.02%	3.17%	103.55%	52.68%
Retained Earnings	-618.57	-594.29	-470.86	-406.86	-281.89	-152.22
Comprehensive Income	-0.05	0.13	-0.15	0	0.01	0.02
Shareholders' Equity	84.59	103.7	187.6	156.21	261.97	-149.51
Net Cash / Debt	114.09	126.78	193.74	145.13	249.84	96.18
Net Cash / Debt Growth	-28.39%	-34.56%	33.50%	-41.91%	159.77%	750.46%
Net Cash Per Share	1.19	1.41	2.69	2.33	6.94	7.62
Working Capital	131.97	155.16	244.68	170.54	283.97	105.32
Book Value Per Share	0.88	1.15	2.61	2.51	7.28	-11.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).